Panitumumab IRDye 800

Phase 1

VVanderbilt-Ingram Cancer Center

Panitumumab IRDye 800 is one of 9 therapeutic programs targeting HNSCC. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HNSCCRecruiting

HNSCCPhase 1

Recruiting

Competition

Competitive Landscape

8 competitors in HNSCC

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 1

2 2

Keytruda

Merck & Co.

Preclinical

1 3

Beyfortus

BeiGene

Preclinical

1 4

SKB571

SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2

1 5

Gilotrif

Boehringer Ingelheim

Preclinical

1 6

Nivo800

VVanderbilt-Ingram Cancer Center

Phase 1

1 7

Panitumumab IRDye 800

VVanderbilt-Ingram Cancer Center

Phase 1

1 8

HCB101

FFBD Biologics Limited

Preclinical

1 9

Lysogenic HSV Virus.

WWest China Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

HNSCC

NCT06819228

Clinical

Trials by Indication[1]

HNSCC1 trial

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

Recruiting·VVanderbilt-Ingram Cancer Center·Phase 1·NCT06819228·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Panitumumab IRDye 800. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Panitumumab IRDye 800. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Vanderbilt-Ingram Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: VVanderbilt-Ingram Cancer Center

Panitumumab IRDye 800

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

HNSCC1 trial

References

Drug Info

Quick Facts

Related News